Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
John G.F. Cleland(University of Glasgow), Alan S. Rigby(University of Hull), Hans Wedel(Sahlgrenska University Hospital), Michael Böhm(Saarland University), Karina V Bunting, Frank Ruschitzka(Kantonsspital St. Gallen), John Kjekshus(Nuffield Health), John J.V. McMurray(University of Glasgow), Marcus Flather(Norfolk and Norwich University Hospital), John Wikstrand(Nuffield Health), Milton Packer(Baylor University Medical Center), Douglas G. Altman(Unknown), Andrew J.S. Coats(The Heart Research Institute), Thomas G. von Lueder(Oslo University Hospital), Jane Holmes(University of Manchester), Giuseppe Rosano(St George's Hospital), Dirk J. van Veldhuisen(University Medical Center Groningen), Luís Manzano(Universidad de Alcalá), Bert Andersson(Sahlgrenska University Hospital), Dipak Kotecha(University Hospitals Birmingham NHS Foundation Trust), Åke Hjalmarson(Sahlgrenska University Hospital)
Cited by 643
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k